The Singapore Chinese Health Study

在这份提案中，我们为新加坡华人健康中心提供了继续基础设施支持的理由 这项研究在20世纪90年代初在新加坡招募了63,257名中国男性和女性。 需要基础设施支持，以维护和加强这种独特癌症的既定基础设施 通过重复收集问卷调查数据和来自队列的生物样本的流行病学队列 参与者。到目前为止，大约20%的队列参与者被诊断出患有癌症；超过 5500名癌症患者提供了在癌症诊断前收集的基线生物样本。在接下来的5年里 多年来，新加坡华人健康研究将增加4000例新的癌症病例，其中2000例 有可用的基线生物标记物，将为基于生物标志物的开发提供独特的资源 癌症流行病学研究。随着对整个队列的全基因组基因分型的完成 外切体基因序列在未来两年内，这一癌症流行病学队列也将提供独特的 研究基因-环境相互作用对癌症风险的机会。一些新的发现 这为我们在美国进行化学预防试验提供了强有力的理由。 人口。利用独特和先进的电子病历和疾病登记系统， 我们几乎完全保留了参与者；只有不到0.1%的原始队列参与者是 已知的是丢失了我们对癌症发病率、癌症死亡率和许多其他慢性疾病的监测和跟踪 由于他们迁出新加坡而引发的疾病。在未来五年的研究期间，我们建议：(一) 继续跟踪所有幸存参与者的癌症发病率、癌症死亡率、特定原因死亡、 和其他非癌症健康成果；(2)维护和更新生物库；(3)更新和整合 来自后续访谈、疾病结局评估、动态生物信息库的所有数据元素 将库存和新的实验室测量数据输入研究项目的主队列数据库；以及(4) 支持和加强创新的癌症流行病学研究，作为队列特定的辅助项目和大型 将财团项目编队。我们预计，这一亚洲群体的现有资源将变得均匀 作为年轻参与者，在未来五年更具科学价值，特别是那些 基线生物样本，将进入癌症最高发病年龄，从而增加 为基于生物标记物的疾病前研究项目提供资源的癌症病例数量。

In this proposal we provide a rationale for continued infrastructure support for the Singapore Chinese Health Study that enrolled 63,257 Chinese men and women at baseline in the early 1990s in Singapore. Infrastructure support is needed to maintain and enhance the established infrastructure for this unique cancer epidemiology cohort with repeated collections of questionnaire survey data and biological samples from cohort participants. To date, approximately 20% of the cohort participants were diagnosed with cancers; more than 5,500 cancer patients provided baseline biological samples collected before cancer diagnosis. In the next 5 years the Singapore Chinese Health Study will accrue an additional 4,000 new cancer cases, 2,000 of them with available baseline biospecimens that will provide unique resources for development of biomarker-based cancer epidemiological studies. With the completion of the genome-wide genotyping on the entire cohort and exosome gene sequence in the next two years, this cancer epidemiology cohort will also provide unique opportunity for examining the gene-environmental interaction on risk of cancer. Some of the novel findings from this Asian population has provided a strong rationale for us to conduct chemoprevention trials in U.S. populations. Leveraging the unique and advanced system of electronic medical records and disease registries, we have virtually full retention of the participants; only less than 0.1% of the original cohort participants were known to be lost to our monitoring and tracking cancer incidence, cancer mortality, and many other chronic diseases due to their migration out of Singapore. During the next 5-year study period, we propose to: (1) continue to follow up for all surviving participants for cancer incidence, cancer mortality, cause-specific death, and other non-cancer health outcomes; (2) maintain and update the biorepositories; (3) update and integrate all data elements from follow-up interviews, assessment of disease outcomes, dynamic biorepository inventories, and new laboratory measurements into the master cohort database for research projects; and (4) support and enhance innovative cancer epidemiological studies as cohort-specific ancillary projects and large cohort consortium projects. We anticipate that the established resources of this Asian cohort will become even more scientifically valuable over the next five years as the young participants, especially those who provided baseline biological samples, will enter into the age of maximal cancer incidence, thereby increasing the number of cancer cases that provide resources for pre-disease biomarker-based research projects.